Biocon Limited
All news and filings related to Biocon Limited.
View all news & filings- High impact
Biocon Limited Successfully Completes ₹4,150 Crore QIP for Biologics Acquisition
Biocon Limited successfully raised ₹4,150 crore via a Qualified Institutions Placement (QIP). The funds will be used to acquire Viatris' stake in Biocon Biologics, making it a wholly owned subsidiary. The integration is expected to be completed by March 31, 2026.
Read the summary - High impact
Biocon Allots 11.26 Cr Shares Via QIP, Raises ₹4,150 Crore
Biocon Limited has allotted 11,26,64,585 equity shares at ₹368.35 per share via Qualified Institutions Placement (QIP). The issue raised approximately ₹4,150 crore. The company's paid-up equity share capital has increased following this allotment. The trading window will reopen on January 17, 2026.
Read the summary - High impact
Biocon Limited Completes QIP, Allots 11.26 Crore Shares Worth ₹4,150 Crore
Biocon Limited has completed its Qualified Institutions Placement (QIP), allotting 11.26 crore equity shares at ₹368.35 each. The company raised ₹4,150 crore (₹41,500 million) through this issuance. The trading window for securities will reopen on January 17, 2026.
Read the summary - Medium impact
Biocon Approves Placement Document for Qualified Institutions Placement
Biocon Limited's Fund Raising Committee approved the Placement Document for its Qualified Institutions Placement (QIP) on January 14, 2026. The QIP involves equity shares with a face value of ₹ 5 each.
Read the summary - Medium impact
Biocon Completes QIP, Allocates 11.26 Cr Shares at ₹368.35
Biocon Limited closed its Qualified Institutions Placement (QIP) on January 14, 2026. The company allocated 11,26,64,585 equity shares at ₹368.35 per share, a 5% discount to the floor price of ₹387.74. The QIP issue opened on January 12, 2026.
Read the summary - Medium impact
Biocon Limited Opens Qualified Institutions Placement at ₹387.74 Per Share
Biocon Limited has opened its Qualified Institutions Placement (QIP) issue on January 12, 2026. The floor price for the issue is set at ₹387.74 per equity share. The company may offer a discount of up to 5% on the floor price. The trading window remains closed.
Read the summary - Low impact
Biocon Limited Approves Unaudited Condensed Consolidated Interim Financial Statements
Biocon Limited's Board of Directors has approved the unaudited condensed consolidated interim financial statements for the six months ended September 30, 2025, and September 30, 2024. The statements are prepared as per Ind AS and include a limited review report from auditors.
Read the summary - Medium impact
Biocon Pharma Receives US FDA Approval for Everolimus Tablets
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received U.S. FDA approval for its ANDA for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths. The drug is indicated for specific patient groups with Tuberous Sclerosis Complex (TSC).
Read the summary - Low impact
Biocon Limited Files Quarterly Dematerialization Certificate for Q3 FY26
Biocon Limited submitted its dematerialization certificate for the quarter ending December 31, 2025. The company's Registrar and Share Transfer Agent, KFin Technologies Limited, confirmed all dematerialization requests were processed within the regulatory timelines.
Read the summary - Low impact
Biocon Sets March 02, 2026 as Record Date for ₹200 Crore Commercial Paper Maturity
Biocon Limited has announced March 02, 2026, as the record date for the maturity of its ₹200 Crore Commercial Paper. The maturity date is set for March 03, 2026. The CP is listed on the National Stock Exchange of India Limited.
Read the summary - High impact
Biocon Biologics to Expand Oncology Portfolio with 3 New Biosimilars, Integrate as Wholly Owned Subsidiary
Biocon Biologics will introduce three new oncology biosimilars: Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company plans to integrate as a wholly owned subsidiary of Biocon Limited by March 31, 2026. Shreehas Tambe will present at the J.P. Morgan Healthcare Conference on January 15, 2026, and participate in a fireside chat on January 13, 2026.
Read the summary - High impact
Biocon Completes BBL Acquisition, Allots 17.12 Cr Shares at ₹405.78
Biocon Limited completed the acquisition of 26,19,17,480 equity shares of Biocon Biologics Limited (BBL) on January 05, 2026. The company allotted 17,12,79,553 equity shares at ₹405.78 per share as consideration. Additionally, Biocon acquired 7,18,34,691 more BBL shares for USD 200 million. Biocon now holds ~94% of BBL.
Read the summary - High impact
Biocon Completes BBL Acquisition, Allots Equity Shares Worth ₹694 Crore
Biocon Limited completed the acquisition of 26,19,17,480 equity shares of Biocon Biologics Limited (BBL) and allotted 17,12,79,553 equity shares on a preferential basis on January 05, 2026. The company also acquired additional BBL shares from Mylan for USD 200 million. Biocon now holds ~94% of BBL.
Read the summary - Low impact
Biocon Completes Early Full Redemption of ₹500 Crore NCDs on Jan 5, 2026
Biocon Limited has completed the early full redemption of its ₹500 Crore NCDs. The company made the payment on January 05, 2026, fulfilling the board's approval from November 11, 2025. The NCDs were originally issued on May 19, 2023.
Read the summary - Low impact
Biocon Limited Issues Commercial Papers Worth ₹200 Crore
Biocon Limited has issued Commercial Papers worth ₹200 Crore with a 60-day tenure. The papers, allotted on January 02, 2026, mature on March 03, 2026, with an interest rate of 6.80%. They are rated IND A1+ and will be listed on NSE.
Read the summary - Medium impact
Biocon Limited Exta-Ordinary General Meeting: All Resolutions Passed Unanimously
Biocon Limited's EGM on December 31, 2025, saw all resolutions passed. Businesses included preferential issuance of equity shares, increasing investment limits, and raising authorized share capital. Material related party transactions, investor rights, and fund-raising were also approved.
Read the summary - Medium impact
Biocon Limited Holds EGM on Dec 31, 2025, Transacts Key Business
Biocon Limited held its EGM on December 31, 2025, to approve six resolutions. Key proposals include increasing authorized share capital, preferential issuance of equity shares, and material related party transactions. The company also discussed fundraising and granting special rights to investors.
Read the summary - Low impact
Biocon Limited: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results
Biocon Limited's trading window will be closed from January 01, 2026. The closure is to prevent insider trading until 48 hours after the declaration of financial results for the quarter and nine months ending December 31, 2025. The Board Meeting date for results declaration will be announced later.
Read the summary - Low impact
Biocon Sets Record Date: March 19, 2026, for ₹1,800 Crore Commercial Paper Maturity
Biocon Limited has set March 19, 2026, as the Record Date for the maturity of its Commercial Paper. The Commercial Paper has an issue size of ₹1,800 Crore and is set to mature on March 20, 2026.
Read the summary - Medium impact
Biocon signs out-licensing deal with Ajanta Pharma for Semaglutide in 26 countries
Biocon Limited has signed an out-licensing agreement with Ajanta Pharma Ltd to market its Semaglutide drug product. Biocon will supply Semaglutide for exclusive and semi-exclusive marketing in 26 countries across Africa, the Middle East, and Central Asia. This partnership aims to expand Biocon's global footprint and improve patient access.
Read the summary - Medium impact
Biocon Biologics Expands Adalimumab Rights with Fujifilm Kyowa Kirin
Biocon Biologics has secured full global rights for its biosimilar Adalimumab (Hulio®) from Fujifilm Kyowa Kirin Biologics. The expanded agreement grants Biocon end-to-end manufacturing and commercialization responsibilities. FKB will receive license fees and royalties. This strategic move aims to enhance affordability and access to biologics for inflammatory diseases.
Read the summary - Medium impact
Biocon Limited Raises ₹1,800 Crore Via Commercial Papers
Biocon Limited has issued Commercial Papers worth ₹1,800 Crores on a private placement basis. The issuance carries an interest rate of 6.85% and matures on March 20, 2026. The CPs are rated IND A1+ and have been placed with SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life Mutual Fund.
Read the summary - Medium impact
Biocon Generics US Facility Receives Voluntary Action Indicated (VAI) Status from US FDA
Biocon Limited's US facility in Cranbury, New Jersey, received a Voluntary Action Indicated (VAI) status from the US FDA. This follows a cGMP inspection conducted between October 6th and October 10th, 2025. The company has been notified of the Establishment Inspection Report (EIR).
Read the summary - Medium impact
Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM for Ninth Consecutive Year
Biocon Biologics has been recognized as an Asia IP Elite for 2025 by IAM for the ninth consecutive year. This award acknowledges the company's exceptional IP value creation and leadership in the region. CEO & MD Shreehas Tambe highlighted the sustained commitment to innovation and IP strategy.
Read the summary - Low impact
Biocon Limited: CRISIL Reaffirms Credit Ratings of AA+/Stable and A1+
CRISIL Ratings has reaffirmed Biocon Limited's credit ratings. The long-term rating stands at CRISIL AA+/Stable and the short-term rating at CRISIL A1+, for total bank loan facilities rated at ₹250 Crore.
Read the summary - Medium impact
Biocon Limited Secures [ICRA]AA+(Stable)/[ICRA]A1+ Rating for Unallocated Instruments
Biocon Limited received a credit rating of [ICRA]AA+(Stable)/[ICRA]A1+ for its ₹450 crore unallocated instruments from ICRA Limited. This rating is associated with Biocon's ongoing acquisition of minority stakes in Biocon Biologics Limited (BBL). The acquisition involves a $1.17 billion transaction funded by share swap and cash, with a QIP planned to fund part of the payment and repay debt.
Read the summary - Medium impact
Biocon Launches Liraglutide (GLP-1) in Netherlands for Diabetes and Obesity
Biocon Limited launched its GLP-1 peptide, Liraglutide, in the Netherlands for diabetes (Diavorin®) and obesity (Vobexoryn®). This follows approval from the Medicines Evaluation Board (MEB). It's the first EU country for Biocon to directly launch Liraglutide under its own brand via partner Pharmamedic B.V.
Read the summary - Medium impact
Biocon Biologics Secures Global License for Biosimilar Aflibercept
Biocon Biologics has signed a settlement and license agreement with Regeneron and Bayer to commercialize its biosimilar Aflibercept (Yesafili®) worldwide. The agreement allows for launches in the UK in January 2026 and other settled countries in March 2026. This expands Biocon Biologics' presence in ophthalmology.
Read the summary - High impact
S&P Global Places Biocon Biologics on Positive CreditWatch Due to Accelerated Debt Reduction
S&P Global Ratings placed Biocon Biologics on CreditWatch with positive implications due to accelerated debt reduction. Biocon plans to make Biocon Biologics a wholly-owned subsidiary by swapping Viatris' US$1 billion CCPS for equity and cash, funded by a ₹45 billion equity issuance. Adjusted debt is expected to fall to ₹120 billion by March 2026.
Read the summary - Low impact
Biocon Limited to meet with Analysts/Institutional Investors
Biocon Limited will be meeting with Analysts/Institutional Investors between 15 Dec 2025 and 19 Dec 2025 in Mumbai. The meetings will be in person/virtual, in 1x1/Group format.
Read the summary - Medium impact
Biocon Limited: Credit Rating Update from India Ratings and Research
India Ratings and Research has assigned and affirmed credit ratings for Biocon Limited's debt instruments and withdrew the rating on non-convertible debentures.
Read the summary - High impact
Biocon Limited Announces Investor Presentation on December 10-11, 2025
Biocon Limited announced an investor presentation for analyst/institutional investor meetings on December 10-11, 2025, and the consolidation of Biocon Biologics Limited into a wholly-owned subsidiary.
Read the summary - Low impact
Biocon Limited Announces Extra-Ordinary General Meeting on December 31, 2025
Biocon Limited will hold an Extra-Ordinary General Meeting (EGM) on December 31, 2025, at 2:30 P.M. (IST) via Video Conferencing. Remote e-voting will be available to members. The remote e-voting period will commence on December 26, 2025.
Read the summary - Medium impact
Biocon Limited to convene EGM on December 31, 2025
Biocon Limited to convene an Extra-Ordinary General Meeting (EGM) on December 31, 2025, to discuss increasing share capital, raising funds, preferential allotment and grant of special rights to investors.
Read the summary - High impact
Biocon Board Approves Share Capital Increase, Biocon Biologics Acquisition & Fund Raising
Biocon's board has approved increasing the share capital, acquisition of equity shares in Biocon Biologics, raising funds, and convening an EGM on December 31, 2025, to seek shareholder approval.
Read the summary - High impact
Biocon Board Approves Capital Increase, Biocon Biologics Acquisition & Fund Raising
Biocon's board approves increasing authorized share capital, acquisition of Biocon Biologics shares, preferential issue of shares worth ₹6,950 crore, fund raising up to ₹4,500 crore and convening an EGM on December 31, 2025.
Read the summary - High impact
Biocon Board Approves Share Capital Increase, Acquisition of Biocon Biologics Shares, and ₹4,500 Crore Fund Raising
Biocon's board approves increasing share capital, acquiring Biocon Biologics shares, raising ₹4,500 Cr, and convening an EGM on December 31, 2025.
Read the summary - High impact
Biocon Board Approves Capital Increase, Biocon Biologics Acquisition & Fund Raising
Biocon's board approves increasing authorized share capital, acquiring Biocon Biologics shares, raising funds, convening an EGM on December 31, 2025, and issuing commercial papers.
Read the summary - High impact
Biocon Board Approves Acquisition of Biocon Biologics Shares & Fund Raising
Biocon's board approves increasing share capital, acquiring Biocon Biologics shares, issuing preferential shares worth ₹6,950 crore, and raising funds up to ₹4,500 crore. EGM scheduled for December 31, 2025.
Read the summary - High impact
Biocon Board Approves Capital Increase, Biocon Biologics Acquisition & Fund Raising
Biocon's board approves share capital increase, acquisition of Biocon Biologics shares, ₹6,950 crore preferential issue, ₹4,500 crore fundraising, ₹1,800 crore commercial papers, and EGM on December 31, 2025.
Read the summary - Medium impact
Biocon Limited Announces Analyst/Institutional Investor Call on December 8, 2025
Biocon Limited will hold an analyst call on December 8, 2025, to discuss Biocon Biologics Limited’s integration with Biocon Limited. An EGM is scheduled on December 31, 2025 and Share Swap Completion Date is January 2, 2026.
Read the summary - Medium impact
Biocon Limited Announces Analyst/Institutional Investor Call on December 8, 2025
Biocon Limited will conduct an analyst call on December 8, 2025, regarding Biocon Biologics integration. An EGM is scheduled for December 31, 2025, with a target share swap date of January 2, 2026.
Read the summary - High impact
Biocon to Integrate Biocon Biologics, Share Swap at ₹405.78/Share
Biocon to integrate Biocon Biologics via share swap, valuing BBL at $5.5B (₹45,650 crore). Aims to raise ₹4,500 crore via QIP. Integration expected by March 31, 2026.
Read the summary - High impact
Biocon Board Approves Capital Increase, Acquisition of Biocon Biologics Shares, Fund Raising & EGM
Biocon board approves increasing authorized share capital, acquisition of Biocon Biologics shares, fund raising of upto ₹4,500 crore and convening an EGM on December 31, 2025.
Read the summary - Medium impact
Biocon Pharma Receives Tentative US FDA Approval for Parkinson’s Drug
Biocon Pharma gets tentative US FDA nod for Carbidopa and Levodopa Extended-Release Capsules used in Parkinson's treatment.
Read the summary - Low impact
Biocon Limited Intimates Analyst/Institutional Investor Meet on 10-11 Dec 2025
Biocon Limited will be meeting with Analysts/Institutional Investors in person/virtually in Mumbai from December 10-11, 2025. The company will not disclose any Unpublished Price Sensitive Information during the meetings.
Read the summary - Medium impact
Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe
Biocon Biologics secures a settlement to commercialize its Denosumab biosimilars in Europe starting December 2, 2025, expanding its reach in oncology and bone health.
Read the summary - Medium impact
Biocon Biologics' Bengaluru facility classified as VAI by US FDA
Biocon Biologics' Bengaluru facility received VAI classification from US FDA following an inspection in August-September 2025, concerning insulin and Pegfilgrastim production.
Read the summary - Medium impact
Biocon Pharma Receives US FDA Approval for Tofacitinib Tablets
Biocon Pharma, a subsidiary of Biocon, received U.S. FDA approval for its ANDA for Tofacitinib Extended-Release Tablets (11mg strength) and tentative approval for 22mg strength, used for treating arthritis and colitis.
Read the summary - High impact
Biocon Reports Strong Q2 FY26 Results, Reduces Debt, and Launches Multiple Biosimilars
Biocon reported strong Q2 FY26 results with 20% revenue growth, significant debt reduction, and multiple biosimilar launches. Profitability improved, with future annual interest savings of ₹300 crores. The company sees positive impacts from FDA's revised guidance.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio